MedTrace Logo

A Study of BBI608 in Adult Patients With Advanced Malignancies

NCT01775423 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2023-11-14

No results posted yet for this study

Summary

This is an open label, single arm, dose escalation study of BBI608 in patients with advanced malignancies.

Conditions

  • Cancer, Advanced Malignancies

Interventions

DRUG

BBI608

Sponsors & Collaborators

  • Sumitomo Pharma America, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2015-08-06
Completion
2015-08-06

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01775423 on ClinicalTrials.gov